<DOC>
	<DOCNO>NCT01877187</DOCNO>
	<brief_summary>The purpose study determine whether Lipiodol use image biomarker , predict tumor response therapy patient primary metastatic liver cancer . Lipiodol-based transarterial chemoembolization ( TACE ) accept standard care procedure unresectable liver lesion several decade . Lipiodol use carrier chemotherapy agent also occlusion agent . In TACE procedure , Lipiodol mix chemotherapy agent ( ) deliver tumor via hepatic artery , cause necrosis target tumor ( ) . Response therapy evaluate every 1 , 3 6 month clinic visit , MRI/ CT scan blood test ( include assessment liver function tumor marker ) . After 6th month , patient follow every 2-3 month period 4 year .</brief_summary>
	<brief_title>Lipiodol Imaging Biomarker Patients With Primary Metastatic Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>1 . 18 year age old . 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 . 3 . Childs class A B ( 9 ) . 4 . Hepatocellular carcinoma ( HCC ) unresectable liverpredominant disease subject HCC refuse surgery subject diagnose hepatic metastasis solid tumor . ( Multifocal HCC acceptable , diffuse HCC ) . 5 . Subject voluntarily participate study sign informed consent . 1 . Contraindications doxorubicin , cisplatin , mytomycinc administration ( specific mixture chemotherapy drug use ) . 2 . Evidence severe uncontrolled systemic disease . 3 . Congestive cardiac failure &gt; NYHA class 2 MI within 6 month , active coronary artery disease , cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin , unstable angina , laboratory find view investigator make undesirable patient participate trial . 4 . Known allergy Lipiodol ( Ethiodol ) , poppy seed oil , iodinate contrast agent ( adequately mitigate preprocedure medication ) . 5 . Main portal vein thrombosis exclude ; segmental branch portal vein thrombosis acceptable . 6 . Subject breastfeeding . 7 . Subject pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Primary liver cancer</keyword>
	<keyword>Metastatic liver cancer</keyword>
</DOC>